Exploring Ciprofol for Sedation in Obese Patients Undergoing Gastrointestinal Endoscopy
Dose Exploration of Ciprofol for Sedation in Gastrointestinal Endoscopic Diagnosis and Treatment of Obese Patients.
This study is testing a new anesthetic called Ciprofol to see if it can safely and effectively sedate obese patients during gastrointestinal endoscopy procedures.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | RenJi Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT05517408 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of Ciprofol, a new anesthetic, for sedation during gastrointestinal endoscopic procedures in obese patients. Ciprofol has demonstrated similar anesthetic efficacy to propofol but at significantly lower dosages, with a favorable safety profile. The study aims to determine the optimal dosage of Ciprofol for effective sedation while minimizing side effects such as injection pain and respiratory depression. Participants will be closely monitored to assess the drug's performance in this specific patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are obese patients aged 18 to 60 who are scheduled for routine gastrointestinal endoscopic diagnosis and treatment.
Not a fit: Patients with a history of substance abuse, severe allergies to certain medications, or those deemed unsuitable by the researcher may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a safer and more effective sedation option for obese patients undergoing gastrointestinal procedures.
How similar studies have performed: Previous studies have shown promising results with Ciprofol, indicating its potential as a viable alternative to traditional anesthetics like propofol.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age, ≤18 and ≤60 years, no gender limit 2. Undergoing routine gastrointestinal endoscopic diagnosis and treatment 3. American Society of Anesthesiologists (ASA) classification I-II 4. Body Mass Index(BMI) ≥28kg/m\^2 5. Clearly understand and voluntarily participate in the study; provide signed informed consent Exclusion Criteria: 1. Unhealthy alcohol drinking, defined by more than three standard drinks per day (≈10 g alcohol , equivalent to 50 g of strong Chinese spirits) 2. Drug abuse history within 3 months before the screening period 3. People who are known to be allergic to eggs, bean products, opioids and other drugs, propofol, etc 4. The researcher believes that patients should not participate in this trial
Where this trial is running
Shanghai
- Renji Hospital — Shanghai, China (Recruiting)
Study contacts
- Study coordinator: diansan su, PhD
- Email: diansansu@yahoo.com
- Phone: 18616514088
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.